1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Healthcare Information Services
Surgical Science Sweden AB (publ)

Surgical Science Sweden AB (publ)

SUS.ST
Surgical Science Sweden AB (publ)SE flagStockholm Stock Exchange
33.30
SEK
-0.02
- -
1.70BMarket Cap
Surgical Science Sweden AB (publ)
SUS.ST
(Stockholm Stock Exchange)

Recent

price

33.30

P/E

ratio

- -

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1.9
3.62
2.97
2.7
3.6
3.05
8.63
15.8
17.33
17.33
19.45
19.15
Revenue per Share
0.07
0.23
-0.13
-0.19
0.45
0.45
2.03
3.7
4.59
2.58
1.31
1.02
Basic EPS, GAAP
-0.03
0.12
-0.06
-0.07
1.64
0.42
0.58
1.87
3.81
1.76
0.6
1.83
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.88
-1.45
-1.19
-1.13
-0.51
0.04
2.08
5.44
10.02
12.58
13.89
14.26
Book Value per Share
-0.36
-0.77
2.61
2.01
2.64
3.02
6.87
9.67
14.33
17.66
17.54
18.3
Tangible Book Value per Share
24
14
19
24
28
34
42
51
51
51
51
51
Basic Weighted Avg Shares
46
52
57
66
102
105
367
803
883
884
992
977
Sales/Revenue/Turnover
3.69
-0.44
-7.31
-6.19
14.95
19.06
15.41
20.25
21.43
16.32
6.94
6.95
Operating Margin (%)
7
9
10
10
15
17
34
52
56
61
83
- -
Depreciation Expense
2
3
-3
-5
13
16
86
188
234
132
67
52
Net Income, GAAP
- -
- -
- -
- -
17.38
20.62
- -
9.7
12.78
16.73
33.27
30.9
Effective Tax Rate (%)
3.47
6.3
-4.49
-6.88
12.41
14.89
23.52
23.42
26.5
14.89
6.73
5.34
Profit Margin (%)
11
2
45
44
73
102
385
520
756
913
892
919
Working Capital
22
19
4
4
2
2
12
15
40
57
56
- -
LT Debt
20
20
83
79
402
427
3,585
4,236
4,345
4,829
4,273
4,416
Total Equity
- -
- -
- -
- -
5.01
3.72
- -
3.73
3.8
2.57
0.99
1.05
Return on Invested Capital (%)
- -
- -
- -
- -
-71.67
-377.36
- -
96.64
55.75
21.83
9.69
7.42
Return on Capital (%)
- -
- -
- -
- -
- -
- -
192.41
103.09
59.49
22.85
9.89
7.44
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
2
2
2
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
56
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
51
51
51
Market Capitalization
4,488
1,658
1,550

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
1,121
1,185
1,187
Cash, Cash Equivalents & STI
597
616
668
Accounts Receivable, Net
144
137
123
Inventories
205
206
207
Total Current Liabilities
268
293
267
Payables & Accruals
- -
- -
- -
ST Debt
2
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
148.1%
151.97%
-11.51%
Free Cash Flow
-288.47%
67.79%
-66.04%
Net Income, GAAP
14.81%
100.42%
-49.24%
Sales/Revenue/Turnover
48.66%
78.24%
12.25%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
188
212
232
252
884
2025
251
209
264
269
992
2026
235
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.47
0.56
0.84
0.71
2.58
2025
0.65
-0.39
0.4
0.65
1.31
2026
0.37
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
1st Group Limited (1ST.AX)
EGF Theramed Health Corp. (TMED.CN)
Accolade, Inc. (ACCD)
Comprehensive Healthcare Systems, Inc. (CMHSF)
Corum Group Limited (COO.AX)
FRISQ Holding AB (publ) (FRISQ.ST)
Business
Surgical Science Sweden AB (publ) develops, manufactures and markets virtual reality simulators and software solutions for evidence-based medical training focused on minimally invasive surgery, endoscopy, ultrasound and team-based procedures; core products include the LapSim laparoscopic training system with modules from basic navigation to advanced suturing, EndoSim for endoscopic exercises including scope handling and loop reduction, TeamSim for operating room team communication and crisis management, and ultrasound simulation technologies; the company also provides customized simulation solutions for medical device companies developing instruments and offers ready-to-use simulators with evidence-based curricula for healthcare professionals. Founded in 1999 and headquartered in Gothenburg, Sweden, Surgical Science operates globally across Europe, North America, South America and Asia, serving teaching hospitals, clinics, medical training centers and MedTech partners with over 8,000 systems delivered and more than 400 validation studies. The company has expanded through strategic acquisitions including Simbionix, Mimic Technologies, SenseGraphics and, most recently, Intelligent Ultrasound Group PLC in December 2024 for approximately SEK 630 million, which strengthens its ultrasound simulation portfolio, establishes a UK research and development hub in Cardiff and enhances commercial presence in the UK market with expected annual cost synergies of SEK 21-28 million.